Consumers across the EU are set to benefit from a new OTC option to relieve allergy symptoms after the European Medicines Agency gave the green light to the centralised switch of Ratiopharm GmbH’s Desloratadine Ratiopharm.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?